Licensing status

Publication and contact information


Pancreatic cancer

Nuclear factor of activated T cells cytoplasmic calcineurin-dependent 1 (NFATc1)

In vitro and mouse studies suggest inhibiting NFATc1 could help treat pancreatic cancers. In transgenic mice expressing proinflammatory, mutant NFATc1 and oncogenic, mutant K-Ras (KRAS), pancreatic tumors developed and survival was decreased compared with that in mice expressing only one of the two mutant genes. In Kras-mutant mice, inhibition of NFATc1 decreased pancreatic epithelial cell proliferation compared with no inhibition and prevented a marker of neoplastic transformation called acinar-to-ductal metaplasia. Next steps include identifying a strategy to specifically inhibit NFATc1 in cancer cells.

SciBX 7(18); doi:10.1038/scibx.2014.523
Published online May 8, 2014

Findings unpatented; licensing status not applicable

Baumgart, S. et al. Cancer Discov.; published online April 2, 2014;
Contact: Volker Ellenrieder, University Medical Center Goettingen, Goettingen, Germany